Myriad Genetics Announces Post-Hoc Analysis Of PRIME Study Showing Treatment Informed By GeneSight Test Led To Faster Initial Remission And Response In Patients With MDD

Author: Benzinga Newsdesk | October 31, 2025 08:08am

Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that treatment informed by the GeneSight® test led to faster initial remission and response in patients with Major Depressive Disorder (MDD). Further, the post-hoc analysis showed that this benefit persisted over six months with no evidence of changing over time.

The PRIME Care study, the largest pharmacogenomic randomized controlled trial in mental health, enrolled 1,944 U.S. Veterans with depression to test whether GeneSight results improved treatment outcomes. Published in the Journal of the American Medical Association (JAMA) in 2022, it found patients whose clinicians had GeneSight results were significantly more likely to achieve remission over 24 weeks.

The post-hoc analysis of the study results explored whether having access to the GeneSight test results increased the rate of remission and response over time and if the effect was persistent.

Published in the Oct. 30, 2025 edition of Frontiers in Pharmacology, the new post-hoc analysis showed that patients who took the GeneSight test were at any given time during the 24-week study period relative to patients receiving usual care:

• 27% more likely to achieve remission from depression
• 21% more likely to experience response (at least a 50% reduction in depressive symptoms)

Myriad Genetics plans to submit these data to payers as part of its ongoing efforts to increase patient access to the GeneSight test and to help patients achieve remission from depression.

Posted In: MYGN